2025
1186-P: A Short-Term Low Carbohydrate Diet Improves Glycemia in Adolescents and Young Adults with Type 1 Diabetes—Results from a Randomized Crossover Study
NALLY L, LUKASIK J, HERZOG R, MITTENDORFER B, GOSS A, SAVOYE M, ROSE P, MCCOLLUM S, SHABANOVA V, SHERR J. 1186-P: A Short-Term Low Carbohydrate Diet Improves Glycemia in Adolescents and Young Adults with Type 1 Diabetes—Results from a Randomized Crossover Study. Diabetes 2025, 74 DOI: 10.2337/db25-1186-p.Peer-Reviewed Original ResearchLow-carbohydrate dietRandomized Crossover StudyCrossover studyCarbohydrate dietPotential treatment optionStandard carbohydrate dietLower glycemic variabilityRandomized Controlled TrialsDietary recallsMetabolic kitchenTreatment optionsIncreasing hypoglycemiaImprove glycemiaGlycemic variabilityControlled TrialsT1DGlycemic benefitsWeekend daysHypoglycemiaIncreasing timeYoung adultsDietYouthGlycemiaHyperglycemia1926-LB: A Qualitative Descriptive Study of Motivation States in Physical Activity among Middle-Aged Adults with Type 1 Diabetes
ASH G, HERNANDEZ E, (VERA) WANG X, GRIGGS S. 1926-LB: A Qualitative Descriptive Study of Motivation States in Physical Activity among Middle-Aged Adults with Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1926-lb.Peer-Reviewed Original ResearchPhysical activityInfluence physical activity engagementPhysical activity engagementQualitative descriptive studyType 1 diabetesMiddle-aged adultsSemi-structured interviewsSedentary timeExercise interventionQualitative descriptive approachMuscle fatigueInductive codingDescriptive studyNeuromuscular taskActive engagementDescriptive approachMotivational stateQuantitative surveyPsychological stateAdultsWAnTInterventionParticipantsPsychological considerationsT1DA Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts
Sosenko J, Cuthbertson D, Jacobsen L, Redondo M, Sims E, Ismail H, Herold K, Skyler J, Nathan B, Groups D. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics 2025, 27: 179-186. PMID: 39757867, PMCID: PMC12084817, DOI: 10.1089/dia.2024.0422.Peer-Reviewed Original ResearchConceptsIndependent of insulin secretionArea under the curveAUC C-peptideAutoantibody-positive individualsC-peptideInsulin secretionAUC glucoseGlucose toleranceFirst-phase insulin responseDiabetes Prevention Trial-Type 1Type 1 diabetes progressionOral glucose tolerance test dataGlucose tolerance test dataPrediction of T1DImpaired glucose toleranceOral glucose toleranceType 1 diabetesDPT-1TrialNet PathwayIncreased glycemiaInsulin responseInverse correlationSecretionT1DLack of correlation
2024
Fear of hypoglycemia relates to glycemic levels during and after real‐world physical activity in adolescents with type 1 diabetes
Patton S, Bergford S, Gal R, Calhoun P, Clements M, Sherr J, Riddell M. Fear of hypoglycemia relates to glycemic levels during and after real‐world physical activity in adolescents with type 1 diabetes. Diabetic Medicine 2024, 42: e15482. PMID: 39645661, DOI: 10.1111/dme.15482.Peer-Reviewed Original ResearchPhysically active youthExercise-induced hypoglycaemiaSelf-reported food intakeType 1 diabetesFear of hypoglycemiaExercise sessionsPost-exercisePhysical activityExercise eventsSelf-ReportExerciseSurveyed childrenActive youthYouth Self-ReportSubscalesScoresYouthGlycemic levelsPercent timeAdolescentsFearContinuous glucose monitoring dataT1DGlycaemiaFood intakeThe Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.
Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.Peer-Reviewed Original Research240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
SHERR J, HAGAN K, BHAK R, PETER M, NGUYEN H, WANG C, PAKALAPATI T, SHERWOOD J, GUPTA T, GAGLIA J, CORNELIUS E, CHAPMAN K, WOLF W, PETTUS J. 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey. Diabetes 2024, 73 DOI: 10.2337/db24-240-or.Peer-Reviewed Original ResearchFollow-up surveySevere hypoglycemic eventsImpaired awareness of hypoglycemiaOnline surveyT1D Exchange RegistryProportion of respondentsT1D careFollow-upEligible individualsHbA1c < 7%Diabetes technologyLongitudinal trendsCGM useHbA1c targetLongitudinal assessmentInsulin delivery methodsHbA1cAwareness of hypoglycemiaSurveyParticipantsImpaired awarenessAdultsT1DRespondentsHypoglycemic events326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
TURNER L, SHERR J, ZAHARIEVA D, BARAN J, BODE B, BROWN S, BZDICK S, MEI CHURCH M, HANSEN D, KINGMAN R, LAFFEL L, SHAH V, STONE S, VIENNEAU T, HUYETT L, DUMAIS B, LY T, RIDDELL M, 5 EXERCISE RESEARCH GROUP O. 326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System. Diabetes 2024, 73 DOI: 10.2337/db24-326-or.Peer-Reviewed Original ResearchGeneralized Estimating EquationsInternational Society for Pediatric and Adolescent DiabetesActivity sessionsEstimating EquationsType 1 diabetesExerciseAdolescent DiabetesAF-30Glucose declineDeliveryInsulin deliveryInsuletSessionsDelivery systemInsulin delivery systemsDiabetesAutomated deliveryOmnipodRiskGlucoseT1DPeopleDigital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study
Patton S, Gal R, Bergford S, Calhoun P, Clements M, Sherr J, Riddell M. Digital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study. JMIR Pediatrics And Parenting 2024, 7: e57198. PMID: 38889077, PMCID: PMC11186795, DOI: 10.2196/57198.Peer-Reviewed Original ResearchExercise sessionsPhysical activityMinutes of physical activityLevels of physical activityRegular physical activityType 1 diabetesCross-sectional analysisDigital gamesHealthy lifestyleActive wearablesGame sessionsExerciseInsulin useNondigital gamesDaily activitiesPediatric studiesSessionsContext of youthDisease statusYouthT1DCharacteristics of digital gamesInsulin pumpObservation periodContinuous glucose monitoringEffects of gut microbiome on type 1 diabetes susceptibility and complications: A large‐scale bidirectional Mendelian randomization and external validation study
Guo K, Ye J, Li J, Huang J, Zhou Z. Effects of gut microbiome on type 1 diabetes susceptibility and complications: A large‐scale bidirectional Mendelian randomization and external validation study. Diabetes Obesity And Metabolism 2024, 26: 3306-3317. PMID: 38751358, DOI: 10.1111/dom.15658.Peer-Reviewed Original ResearchHigh-density lipoproteinOphthalmic complicationsT1D complicationsComplications of type 1 diabetesType 1 diabetes susceptibilityData of patientsRisk of T1DSmall high-density lipoproteinGut microbiomeComplications of T1DType 1 diabetesEffect of gut microbiomeExternal validation studyEffects of gut microbiotaCirculating metabolitesMultivariable MR analysisHealthy controlsComplicationsMR analysisMendelian randomizationRelative abundanceEubacterium coprostanoligenes groupMetabolic diseasesT1DPatientsPredicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes
Bergford S, Riddell M, Gal R, Patton S, Clements M, Sherr J, Calhoun P. Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 728-738. PMID: 38669475, DOI: 10.1089/dia.2024.0061.Peer-Reviewed Original ResearchRepeated measures logistic regressionPhysically active adolescentsHyperglycemia riskType 1 diabetesMeasures logistic regressionComposite riskAcute glucose responseGlucose rateWearing continuous glucose monitoringContinuous glucose monitoringReceiver operating characteristic curveArea under the receiver operating characteristic curveRisk of hypoglycemiaLogistic regressionActive adolescentsHbA1c levelsActivity startExerciseAdolescentsRiskCharacteristic curveHypoglycemiaGlucose responseHyperglycemiaT1DReal-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Forlenza G, DeSalvo D, Aleppo G, Wilmot E, Berget C, Huyett L, Hadjiyianni I, Méndez J, Conroy L, Ly T, Sherr J. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 514-525. PMID: 38375861, DOI: 10.1089/dia.2023.0578.Peer-Reviewed Original ResearchGlucose targetsType 1 diabetesSubgroup analysisGlycemic outcomesReal-world evidenceMultiple daily injectionsYounger age groupsBaseline characteristicsDaily injectionsRetrospective analysisClinical trialsMedian percentageAge groupsResults:</i></b>OmnipodDelivery systemOutcomesInsulin delivery systemsT1DSubgroupsDiverse sampleThe immunology of type 1 diabetes
Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.Peer-Reviewed Original ResearchType 1 diabetesT cellsDestruction of pancreatic B-cellsImmune-targeted interventionsTarget T cellsPathogenesis of T1DB-cell massPancreatic B-cellsAutoimmune destructionB cellsGlucose dysregulationImmune mechanismsImmune systemNatural historyDisease pathogenesisT1DRegulatory approvalTreatment of individualsDiscovery of insulinPathogenesisDiseaseSeminal discoveriesImmunotherapyPostprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2023
Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study
Hu J, Ding J, Li X, Li J, Zheng T, Xie L, Li C, Tang Y, Guo K, Huang J, Liu S, Yan J, Peng W, Hou C, Wen L, Xu A, Zhou Z, Xiao Y. Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study. EClinicalMedicine 2023, 62: 102132. PMID: 37593224, PMCID: PMC10430172, DOI: 10.1016/j.eclinm.2023.102132.Peer-Reviewed Original ResearchAdult-onset T1DHealthy controlsGut microbiotaT1D patientsShort-chain fatty acid-producing bacteriaPopulation-based cross-sectional studyGut microbial alterationsRecent epidemiological dataType 1 diabetesCross-sectional studyT2D patientsIntestinal disturbancesDifferential diagnosisSerum metabolitesEpidemiological dataPatientsStudy subjectsT1DDiabetesSignificant differencesAcid-producing bacteriaMicrobiotaMicrobial profilesNational Key ResearchMicrobial alterationsBeta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatment
2022
Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdultsThe global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis
Rahmati M, Keshvari M, Mirnasuri S, Yon D, Lee S, Shin J, Smith L. The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis. Journal Of Medical Virology 2022, 94: 5112-5127. PMID: 35831242, PMCID: PMC9350204, DOI: 10.1002/jmv.27996.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisNew-onset T1DDiagnosed T1D childrenDiabetic ketoacidosisType 1 diabetesHbA1c valuesT1D childrenMeta-analysisNew-onset type 1 diabetesPre-COVID-19 pandemic levelsRisk of T1DRandom-effects meta-analysisGlobal incidence rateMedian glucosePediatric patientsPhysician awarenessViral infectionRelative riskIncidence rateCoronavirus disease 2019Pre-COVID-19T1DHbA1cCOVID-19 pandemicPandemic levelsFibronectin-Integrin α5 Signaling in Vascular Complications of Type 1 Diabetes.
Chen M, Hu R, Cavinato C, Zhuang ZW, Zhang J, Yun S, Fernandez Tussy P, Singh A, Murtada SI, Tanaka K, Liu M, Fernández-Hernando C, Humphrey JD, Schwartz MA. Fibronectin-Integrin α5 Signaling in Vascular Complications of Type 1 Diabetes. Diabetes 2022, 71: 2020-2033. PMID: 35771994, PMCID: PMC9450851, DOI: 10.2337/db21-0958.Peer-Reviewed Original ResearchConceptsVascular complicationsInjection of streptozotocinBlood flow recoveryHigh-fat dietType 1 diabetesInflammatory cell invasionIntegrin α5T1D miceVascular basement membraneVascular diseaseCarotid arteryHindlimb ischemiaMetalloproteinase expressionMain receptorType 1Plaque sizeBeneficial effectsEndothelial cellsMajor causeCell invasionExtracellular matrix proteinsHyperlipidemiaComplicationsBasement membraneT1DGene Expression Signatures Reveal Common Virus Infection Pathways in Target Tissues of Type 1 Diabetes, Hashimoto’s Thyroiditis, and Celiac Disease
Yin M, Zhang Y, Liu S, Huang J, Li X. Gene Expression Signatures Reveal Common Virus Infection Pathways in Target Tissues of Type 1 Diabetes, Hashimoto’s Thyroiditis, and Celiac Disease. Frontiers In Immunology 2022, 13: 891698. PMID: 35795668, PMCID: PMC9251511, DOI: 10.3389/fimmu.2022.891698.Peer-Reviewed Original ResearchConceptsHashimoto's thyroiditisCeliac diseaseAutoimmune diseasesTarget tissuesAutoimmune disordersHuman T-lymphotropic virus type 1Type 1 diabetes patientsMore autoimmune disordersPathogenesis of T1DType 1 diabetesCommon gene expression changesVirus type 1Gene expression signaturesSimplex infectionVirus infection pathwaysDiabetes patientsInfluenza APositive individualsVirus infectionT1DThyroiditisImmune systemType 1Gene signatureSimilar molecular signatures765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply